Biovica Q1 FY27 operating loss widens to SEK 20.33 million; net sales rise 56% to SEK 4.04 million

• Biovica posted Q1 net sales of SEK 4.04 million, up 56% year over year, driven by continued strong momentum in Pharma Services.
• Operating loss widened to SEK 20.33 million, including SEK 2.2 million in restructuring costs tied to organizational changes and streamlining actions.
• Cash flow from operating activities improved to negative SEK 16.1 million, while cash and cash equivalents climbed to SEK 51.59 million.
• Management highlighted a refocused US commercial strategy, including terminating the reference lab agreement with Tempus AI, while test volumes grew about 20%.
• The board proposed a fully guaranteed SEK 29.2 million rights issue, with the subscription period expected to open no later than Oct. 7, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.